Industry
Biotechnology
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Loading...
Open
2.24
Mkt cap
2.5M
Volume
1.9M
High
2.35
P/E Ratio
-0.13
52-wk high
22.35
Low
1.71
Div yield
N/A
52-wk low
1.38
Portfolio Pulse from
December 03, 2024 | 1:30 pm
Portfolio Pulse from
November 21, 2024 | 1:30 pm
Portfolio Pulse from Benzinga Insights
October 31, 2024 | 8:34 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 5:02 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 12:47 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 12:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 25, 2024 | 12:08 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.